Published On : September 2026
The type of organisation developing a nanoformulation-based pain treatment, whether a large pharmaceutical company, a specialty drug developer, a contract development and manufacturing organisation, or a research institution, shapes which business model that organisation is realistically able to pursue, since in-house development, licensing and co-development, and outsourced formulation work each require different internal capability.
An organisation's existing manufacturing footprint, regulatory experience and balance sheet all factor into which business model is realistic for it, which is why the same nanoformulation opportunity can look like an in-house development project for one organisation and an outsourcing or licensing opportunity for another.
These decisions are rarely made once and left unchanged, since an organisation's business model choice for a given nanoformulation programme can shift as that programme matures, moving for example from an early licensing arrangement toward in-house commercialisation once internal capability has been built up.
This page sets out the four end-user types and three business models this report tracks, and explains how organisational scale and capability connect the two in practice.
The overall scope this end-user and business-model structure sits within is covered on the nanoformulation-based pain treatment technology market overview.
Pharmaceutical companies represent the broadest end-user category, spanning organisations that develop, register and commercialise nanoformulation-based pain treatments across multiple drug classes and pain categories at once. Their scale typically allows them to maintain in-house formulation science capability alongside external partnerships where it makes strategic sense.
Specialty drug developers concentrate on a narrower set of pain-focused programmes, often building deep formulation expertise in a specific nanoformulation type or pain treatment category rather than pursuing a broad portfolio. This focus can make them attractive licensing partners for larger organisations seeking access to a specific technical capability.
Contract development and manufacturing organisations supply the nanoparticle production, formulation science and manufacturing capability that other end-users increasingly rely on rather than building that infrastructure in-house themselves. Their role has expanded as pain-focused nanoformulation development has grown across a wider range of organisation sizes.
Research institutions and clinical labs contribute early-stage discovery and characterisation work, often ahead of any formal development or commercialisation partnership being established with an industry partner. Much of this work eventually feeds into a licensing arrangement once a candidate formulation shows sufficient promise to attract commercial interest.
These four end-user types are not evenly represented at every stage of a nanoformulation's development. Research institutions and clinical labs are most active at the discovery stage, specialty drug developers and contract development and manufacturing organisations are most active through formulation and preclinical development, and pharmaceutical companies tend to become more central as a programme approaches regulatory filing and commercialisation.
A given nanoformulation programme can therefore pass through the hands of more than one end-user type before it reaches commercial availability, with each type contributing the specific capability it is best positioned to provide at that stage of development.
This handoff pattern means the relationships between end-user types matter as much as the capabilities of any single type on its own, since a discovery-stage insight from a research institution only becomes commercially useful once it is picked up and carried forward by a specialty drug developer, contract manufacturer or pharmaceutical company.
Buyers mapping this end-user landscape for their own planning purposes typically find it useful to identify not just which type of organisation they themselves represent, but which other end-user types they are most likely to need to work with as their own nanoformulation programme advances, since planning those relationships early tends to reduce delays later in development.
In-house drug development keeps formulation science, manufacturing and regulatory work inside a single organisation, a model more accessible to end-users that already operate their own nanoparticle production capability. It offers the greatest degree of control but also requires the largest sustained capital investment.
Licensing and co-development partnerships allow an organisation with a promising nanoformulation platform to pair with a partner that has complementary drug class expertise, regulatory experience or commercial infrastructure it does not have on its own. This model spreads both the cost and the risk of development across two or more organisations.
CDMO-based formulation outsourcing lets end-users access nanoparticle production and formulation science capability without building that infrastructure internally, a model that has become increasingly common as contract development and manufacturing organisations expand pain-focused formulation capacity. It typically involves less upfront capital commitment than in-house development, in exchange for less direct control over the manufacturing process.
None of the three business models is exclusive in practice: a single organisation might pursue in-house development for one nanoformulation programme while simultaneously licensing a different platform from an outside partner and outsourcing a third programme's manufacturing to a contract development and manufacturing organisation.
The choice of business model also has implications for how quickly a programme can move forward: CDMO-based outsourcing can shorten the time to first manufactured batch for an organisation without existing infrastructure, while in-house development, once that infrastructure exists, can shorten the time needed to coordinate across an external partner's own scheduling and capacity constraints.
Risk allocation differs across the three models as well, with in-house development concentrating both the cost of failure and the reward of success inside a single organisation, while licensing, co-development and CDMO-based outsourcing each spread part of that risk across more than one party.
Organisations frequently revisit their business model choice as a nanoformulation programme moves between stages, since the capability and risk profile that made sense at the discovery stage does not necessarily remain the best fit once a candidate advances toward regulatory filing and commercial launch.
|
PROCUREMENT INSIGHT CDMO-based formulation outsourcing has grown alongside a broader pharmaceutical industry pattern of separating formulation science capability from commercial and regulatory ownership, which lets a specialty drug developer or emerging startup pursue a nanoformulation programme without the multi-year capital commitment that building in-house nanoparticle manufacturing would otherwise require. |
A specialty drug developer without in-house nanoparticle manufacturing capability is a more natural candidate for CDMO-based formulation outsourcing than a large pharmaceutical company that already operates its own formulation infrastructure, while a research institution's discovery-stage work is more likely to feed into a licensing arrangement than into direct in-house commercialisation.
An emerging startup, similarly, is more likely to combine a licensing or co-development arrangement with CDMO-based outsourcing than to attempt full in-house development, since it typically has neither the manufacturing infrastructure nor the commercial and regulatory experience that in-house development at scale requires.
A large pharmaceutical company, by contrast, may still choose CDMO-based outsourcing for a specific nanoformulation type it does not manufacture in-house, even while pursuing in-house development for other programmes built on platforms it already has established production capability for.
Regulatory pathway status is one further factor that shapes which business model makes sense at a given stage, a relationship covered directly in the analysis of regulatory pathway considerations for nanoformulation-based pain treatments.
Buyers selecting a development or outsourcing partner weigh manufacturing scalability, formulation science track record across relevant nanoformulation types, and the partner's experience navigating the regulatory pathway relevant to the intended pain treatment category and drug class.
Cultural and operational fit also matters in a licensing or co-development arrangement specifically, since the two organisations typically need to coordinate closely across development, regulatory and eventually commercial functions over a multi-year relationship.
Financial terms and intellectual property arrangements are negotiated differently across the three business models as well, with in-house development keeping intellectual property fully internal, licensing and co-development typically sharing it between partners under negotiated terms, and CDMO-based outsourcing usually keeping intellectual property with the end-user while the contract manufacturer is compensated for production services.
The full landscape of providers evaluated against these criteria, grouped by genuine business type, is set out among the leading nanoformulation companies covered in this report.
Four end-user types are tracked: pharmaceutical companies, specialty drug developers, contract development and manufacturing organisations, and research institutions and clinical labs, each playing a different role in the development chain.
It is a business model in which an end-user relies on a contract development and manufacturing organisation for nanoparticle production and formulation science capability, rather than building that infrastructure internally, typically in exchange for less direct control over the manufacturing process.
In-house drug development keeps formulation, manufacturing and regulatory work inside a single organisation and offers the greatest degree of control, while licensing and co-development partnerships combine a nanoformulation platform from one organisation with complementary expertise or infrastructure from a partner, spreading cost and risk across both.
They supply the specialised nanoparticle production and formulation science capability that many pharmaceutical companies and specialty drug developers do not maintain in-house, making CDMO-based outsourcing an increasingly common business model as pain-focused nanoformulation activity expands.
Specialty drug developers and emerging startups without in-house nanoparticle manufacturing capability are the end-user types most likely to rely on CDMO-based formulation outsourcing, compared with large pharmaceutical companies that often already operate their own formulation infrastructure.
Yes. None of the three business models is exclusive in practice: an organisation might pursue in-house development for one nanoformulation programme while licensing a different platform from a partner and outsourcing a third programme's manufacturing to a contract development and manufacturing organisation.
In-house development keeps intellectual property fully internal, licensing and co-development typically share it between partners under negotiated terms, and CDMO-based outsourcing usually keeps intellectual property with the end-user while the contract manufacturer is compensated for production services.